Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction
Brian Drachman(Penn Presbyterian Medical Center), Pablo García‐Pavía(Universidad Francisco de Vitoria), Ronnie Wang(Pfizer (United States)), Thibaud Damy(Amyloidosis Foundation), Franca S. Angeli(Pfizer (United States))
Cited by 11
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k